



DLA Piper Global Life Sciences Sector



Knowledge sharing

Leveraging our collective knowledge develop market-leading products

Sharing knowledge and insights

We leverage the collective knowledge and experience of our dedicated Life Sciences sector group across the globe to develop market-leading products and thought-leadership that provide our clients with the intelligence and insight they need to gain a competitive advantage.



Cortex – Life Sciences Insights

Our Cortex blog features articles and updates regarding the latest global developments in the Life Sciences sector, including new legislation, trends and products.

You can access the blog [here](#):




Cross border Guide to Clinical Trials and Privacy

Clinical trials often take place on a cross-border basis, involving sites in a number of different jurisdictions.

Experience shows that it can be difficult to understand and manage the privacy requirements for cross-border trials due to differences in local law and interpretation relating to the interplay between privacy laws and clinical trials.

This guide, created by privacy professionals from our global Life Sciences sector team, covers privacy requirements in 25 jurisdictions and provides useful guidance for industry stakeholders.

To find out more, please visit the interactive guide [here](#).



Telehealth around the world: A global guide

The COVID-19 pandemic has caused healthcare systems around the globe to rapidly, and in some cases, radically rethink the delivery of medical care. The global expansion of telehealth services is one way we have seen this transformation occur, which has resulted in significant opportunities in the field, as well as unprecedented regulatory change.

This global guide provides an overview of the current state of telehealth regulations worldwide and assists readers to identify the opportunities, challenges and risks, on a country-by-country basis.

To find out more, please visit the site [here](#):

Sharing knowledge and insights

We leverage the collective knowledge and experience of our dedicated Life Sciences sector group across the globe to develop market-leading products and thought-leadership that provide our clients with the intelligence and insight they need to gain a competitive advantage.



Global Compliance Guide for Engaging Healthcare Professionals

DLA Piper's global Life Sciences team have prepared an interactive comparison site to give you an overview of global compliance requirements and restrictions applying to pharmaceutical companies wishing to interact with healthcare professionals in over 35 jurisdictions worldwide. The site outlines the limitations set by local rules, including law, guidance and codes of conduct concerning hospitality offered by pharmaceutical companies to healthcare professionals.

Please visit the site [here](#)



Global M&A Intelligence Report 2023 & Life Sciences Supplement

This report provides an insight into life sciences M&A deal activity in 2022 and supplements our 2023 global M&A intelligence report, which is now in its ninth edition.

The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.

Request the report [here](#)



Digital Therapeutics

DLA Piper's Life Sciences sector group in conjunction with The Lawyer produced this detailed research report which seeks to understand the current developments in the field of digital therapeutics. The report looks at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

To find out more, please download a copy of the report [here](#):

Sharing knowledge and insights

We leverage the collective knowledge and experience of our dedicated Life Sciences sector group across the globe to develop market-leading products and thought-leadership that provide our clients with the intelligence and insight they need to gain a competitive advantage.



High Growth Startup Pack 2.0

This Startup Pack has been designed and prepared by DLA Piper's Emerging Growth and Venture Capital Team with input from lawyers with experience in corporate, intellectual property and commercial contracting, data protection, employment, employment benefit and tax matters.

The purpose of this Startup Pack is to provide assistance and support to early stage startups and high growth enterprises looking to establish their business on a more formal basis in England & Wales and Ireland. The Startup Pack is suitable for companies looking to raise external capital for the first time, either from family and friends, or angel and seed-level institutional investors.

[Click here to access.](#)



At the Intersection of Science and Law Podcast Series

In DLA Piper's At the Intersection of Science and Law podcast series, members of the firm's Life Sciences team will explore the connection between science and the law in areas including AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

To listen to the series, [click here](#).



Lit and Reg webinar series

Starting on 22 June 2023

A series of webinars considering the emerging regulatory and litigation risks for the Life Sciences industry in Europe.

The opening session will cover:

- the size and scope of the risk facing businesses;
- European vs American litigation landscape;
- introduction to two specific litigation risks: product liability and sustainability; and.
- what actions businesses can take to prevent and defend litigation.

For more information, contact [Carly Chadwick](#).

DLA Piper is a global law firm operating through various separate and distinct legal entities. Further details of these entities can be found at www.dlapiper.com.

This publication is intended as a general overview and discussion of the subjects dealt with, and does not create a lawyer-client relationship. It is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. DLA Piper will accept no responsibility for any actions taken or not taken on the basis of this publication. This may qualify as “Lawyer Advertising” requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Copyright © 2021 DLA Piper. All rights reserved.